Digital Coming soon: New EU Artificial Intelligence Act Everyone is talking AI these days – and regulators are taking notice.
R&D Rare Disease Day: Enhancing clinical trial success in rare d... Rare diseases impact an estimated 300 million people globally, while around one in five cancers are considered a rare disease.
Market Access Six takeaways from JP Morgan 2024 With another JP Morgan in the rearview mirror, it’s time to take stock of the announcements, the presentations, and, above all, the vibes.
Webinars Sponsored Synthetic control arms in clinical trials: Making it happen Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.
R&D Sponsored How synthetic control arms are changing clinical trials Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
